Alto Neuroscience (NYSE:ANRO) Trading Down 5.5% - What's Next?

Key Points

• ANRO fell 5.5% to $20.29 on Monday with ~243,187 shares traded (≈3% above average), and the stock is trading above its 50- and 200-day moving averages ($18.47 and $13.74).
• Analysts are mixed but tilted positive — five Buys, one Hold and one Sell give a consensus of "Moderate Buy" with an average price target of $34.33; recent notable targets include Robert W. Baird raising to $41 and Wedbush to $22.
• Alto reported a quarterly EPS of −$0.45, beating estimates of −$0.56 by $0.11, and it shows strong liquidity (current and quick ratio 15.69) and low leverage (debt/equity 0.12) while analysts forecast a full-year EPS of −2.54.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) dropped 5.5% on Monday . The company traded as low as $20.34 and last traded at $20.2930. Approximately 243,187 shares changed hands during trading, an increase of 3% from the average daily volume of 235,854 shares. The stock had previously closed at $21.47.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Alto Neuroscience from a "hold" rating to a "sell" rating in a report on Saturday. Wedbush lifted their target price on Alto Neuroscience from $13.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, March 17th. Robert W. Baird boosted their target price on Alto Neuroscience from $22.00 to $41.00 and gave the company an "outperform" rating in a research note on Wednesday, March 18th. Weiss Ratings restated a "sell (e+)" rating on shares of Alto Neuroscience in a report on Monday, December 29th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $30.00 price target on shares of Alto Neuroscience in a research report on Tuesday, March 17th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $34.33.

Alto Neuroscience Price Performance

The company's 50-day moving average price is $18.47 and its 200-day moving average price is $13.74. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. The company has a market cap of $640.60 million, a P/E ratio of -9.20 and a beta of 2.51.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.11. As a group, sell-side analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. bought a new position in shares of Alto Neuroscience during the first quarter worth about $67,000. AQR Capital Management LLC bought a new stake in Alto Neuroscience in the 1st quarter valued at approximately $52,000. Bank of Montreal Can acquired a new position in Alto Neuroscience during the 2nd quarter worth approximately $25,000. AlphaCore Capital LLC grew its stake in shares of Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company's stock worth $44,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Alto Neuroscience by 9.9% during the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company's stock worth $2,062,000 after acquiring an additional 84,417 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.